Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | DHODH | Q02127 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 2/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | PRKCA | P17252 | 1/20 | 0.45 |
| ▸ | ABL2 | P42684 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7443977 | 0.81 | NOS3 (0.47) | KMT2AMEN1DHODHABL1EGFR | |
| Hydrochloric Acid SCHEMBL11127891 | 0.80 | NOS3 (0.46) | KMT2AMEN1DHODHABL1EGFR | |
| SCHEMBL7236672 | 0.78 | NPC1 (0.60) | KMT2AMEN1DHODHCYP1A2CYP3A4 | |
| SCHEMBL9488233 | 0.78 | DHODH (0.55) | KMT2AMEN1DHODHEGFRMAPT | |
| SCHEMBL2037022 | 0.77 | DHODH (0.57) | KMT2AMEN1DHODHABL1EGFR | |
| SCHEMBL1854360 | 0.75 | MAPK10 (0.38) | DHODHRAB9ANPC1CDK2NOS3 | |
| SCHEMBL10814167 | 0.75 | MAPT (0.57) | KMT2AMEN1DHODHEGFRCYP1A2 | |
| SCHEMBL28531510 | 0.74 | SRC (0.47) | KMT2AMEN1DHODHCYP1A2CYP3A4 | |
| SCHEMBL17154860 | 0.74 | SLC2A1 (0.54) | DHODHCYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL28811513 | 0.73 | CXCR2 (0.42) | DHODHCYP1A2CYP3A4CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9908877-B2 | Imidazo[1,5-a]pyridinium ion fluorophores, and methods of making and using the same | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-03-06 | — | — | US | claimed |
| US-20160264571-A1 | IMIDAZO[1,5-a]PYRIDINIUM ION FLUOROPHORES, AND METHODS OF MAKING AND USING THE SAME | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-09-15 | — | — | US | claimed |
| US-9371448-B2 | Imidazo[1,5-a]pyridinium ion fluorophores, and methods of making and using the same | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-06-21 | — | — | US | claimed |
| US-20140248646-A1 | IMIDAZO[1,5-a]PYRIDINIUM ION FLUOROPHORES, AND METHODS OF MAKING AND USING THE SAME | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2014-09-04 | — | — | US | claimed |
| EP-3430013-A1 | CARBAPENEM COMPOUNDS | Orchid Pharma Limited (IN) | 2019-01-23 | — | — | EP | disclosed |
| US-9908877-B2 | Imidazo[1,5-a]pyridinium ion fluorophores, and methods of making and using the same | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-03-06 | — | — | US | disclosed |
| WO-2017158616-A1 | CARBAPENEM COMPOUNDS | ORCHID PHARMA LTD. (IN) | 2017-09-21 | — | — | WO | disclosed |
| US-20160264571-A1 | IMIDAZO[1,5-a]PYRIDINIUM ION FLUOROPHORES, AND METHODS OF MAKING AND USING THE SAME | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-09-15 | — | — | US | disclosed |
| US-9371448-B2 | Imidazo[1,5-a]pyridinium ion fluorophores, and methods of making and using the same | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-06-21 | — | — | US | disclosed |
| US-20140248646-A1 | IMIDAZO[1,5-a]PYRIDINIUM ION FLUOROPHORES, AND METHODS OF MAKING AND USING THE SAME | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2014-09-04 | — | — | US | disclosed |
| US-7378412-B2 | Pharmaceutical compounds | NICOX S.A. (FR) | 2008-05-27 | — | — | US | disclosed |
| EP-1861100-A1 | 3 , llB-CIS-DIHYDROTETRABENAZINE FOR THE TREATMENT OF A PROLIFERATIVE DISEASE OR AN INFLAMMATION | Cambridge Laboratories (Ireland) Limited (IE) | 2007-12-05 | — | — | EP | disclosed |
| WO-2007017643-A1 | 3 , llB-CIS-DIHYDROTETRABENAZINE FOR THE TREATMENT OF A PROLIFERATIVE DISEASE OR AN INFLAMMATION | CAMBRIDGE LABORATORIES (IRELAND) LIMITED (IE) | 2007-02-15 | — | — | WO | disclosed |
| US-20050261242-A1 | Pharmaceutical compounds | NICOX, S.A. | 2005-11-24 | — | — | US | disclosed |
| US-6344561-B2 | TREATMENT OF SKIN DISORDERS, INFLAMMATION, NERVE SYSTEM DISORDERS, CANCER | ALLERGAN SALES, INC. | 2002-02-05 | — | — | US | disclosed |
| WO-1991017172-A1 | NOVEL MYCALAMIDES WITH ANTITUMOR AND ANTIVIRAL ACTIVITY | HARBOR BRANCH OCEANOGRAPHIC INSTITUTION, INC. (US) | 1991-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261242-A1 | Pharmaceutical compounds | CYP2B6, CYP2C19, MAOB | KMT2A 1777/4885MEN1 1886/4885DHODH 621/4885 |
| US-20160264571-A1 | IMIDAZO[1,5-a]PYRIDINIUM ION FLUOROPHORES, AND METHODS OF MAKING AND USING THE SAME | H1-5, IK, H1-0 | KMT2A 2509/4885MEN1 1006/4885DHODH 2220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.